One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Actuate Therapeutics, Inc. Common stock
ACTU · NGM · Healthcare · Biotechnology
Current price
$0.56
52-week range
$0.41 - $7.90
Market cap
$13.51M
Balance sheet
Healthy
-1,110.88x Concerning
Net cash $4.43M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics develops new medicines to fight cancer, and their main product is a potential treatment for pancreatic cancer that is currently being tested in a study. The money they make primarily comes from research funding and any future sales of their medicines once they are approved. This matters because developing new drugs is a long and expensive process, and investors are watching to see if these new treatments will be successful and generate revenue.
How the company got here
Actuate Therapeutics, originally founded as Apotheca Therapeutics, Inc. in 2015, is a biopharmaceutical company focused on developing treatments for challenging cancers. The company changed its name to Actuate Therapeutics, Inc. in October 2015. Its journey has been centered on the development of a specific type of drug candidate, elraglusib, which targets a key enzyme involved in cancer cell survival and growth. The company's progress is marked by its progression through various stages of clinical trials, aiming to validate the effectiveness and safety of its lead therapy.
What it actually does
Actuate Therapeutics is dedicated to creating new medicines for cancers that are difficult to treat. They focus on a specific biological pathway in cancer cells that helps them survive and grow. By developing a drug that targets this pathway, Actuate aims to make cancer treatments more effective and overcome resistance that cancer cells can develop against existing therapies. Their work is in the clinical stage, meaning their potential medicines are being tested in people to see if they work and are safe.
Elraglusib for Cancer Treatment
The company's main focus is on its product candidate, elraglusib. This is a type of drug known as a glycogen synthase kinase-3 (GSK-3) inhibitor. Think of GSK-3 as a master switch that cancer cells use to keep themselves alive and growing. Elraglusib is designed to block this switch, potentially stopping cancer in its tracks. It's currently being studied in clinical trials for different types of cancer, including pancreatic cancer and certain pediatric cancers like Ewing sarcoma and neuroblastoma. The U.S. Food and Drug Administration (FDA) has given elraglusib special designations, like Fast Track and Orphan Drug, for pancreatic cancer, which can help speed up its development and review process.
What management is betting on now
Actuate Therapeutics' current strategy heavily relies on advancing elraglusib through clinical trials and exploring its potential in combination with other cancer therapies. Management is particularly focused on investigating how elraglusib can work alongside emerging treatments that target specific genetic mutations in cancer, such as RAS inhibitors. The goal is to create more powerful, multi-pronged attacks against difficult-to-treat cancers, aiming to overcome resistance and improve patient outcomes. They are also looking to present promising data from their ongoing studies to support future development and potential regulatory approvals.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-4.87M
Diluted EPS
-0.20
Operating cash flow
$-4.41M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-5.63M
Diluted EPS
-0.24
Operating cash flow
$-5.02M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-4.55M
Diluted EPS
-0.19
Operating cash flow
$-3.74M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-5.41M
Diluted EPS
-0.25
Operating cash flow
$-6.68M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-5.95M
Diluted EPS
-0.30
Operating cash flow
$-4.17M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-6.32M
Diluted EPS
-0.32
Operating cash flow
$-4.62M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-6.45M
Diluted EPS
6.89
Operating cash flow
$-4.77M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-5.97M
Diluted EPS
-0.55
Operating cash flow
$-9.15M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.56
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $4.4M - more cash than debt. Interest coverage -1110.9x.
Net debt
$-4.43M
Interest coverage
-1,110.88x
Actuate Therapeutics, Inc. Common stock's profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 5 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
ACTU
BASELINE
Actuate Therapeutics, Inc. Common stock
Total debt $0.00 Interest coverage -1,110.88x This is the baseline the peer rows are being compared against.
Total debt $127.21K Interest coverage -303.37x Neither company has much profit cushion over interest right now.
Total debt $22.34M Interest coverage -8.13x Neither company has much profit cushion over interest right now.
Total debt $80.62M Interest coverage -7.45x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -16.17x Neither company has much profit cushion over interest right now.
Total debt $1.95M Interest coverage -92.91x Neither company has much profit cushion over interest right now.
What you should know
The case for and against ACTU
0 Rewards
1 Risk
Rewards
Risks
-
Insider ownership is only 15.4% (peer median: 18.7%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.85x
P/B
13.72x
P/S
—
EV/EBITDA
—
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
—
ROA
-213.4%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
1.25x
Quick ratio
1.16x
Total debt
$0.00
Total cash
$4.43M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-0.87
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-19.84M
Free CF TTM
$-19.21M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—